ORIC Pharmaceuticals Inc
ORICHealthcare|Biotechnology|USA
$10.85
-0.09 (-0.82%)
Tangible Book
$4.02
Earnings Power
$2.52
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05315700 Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Solid Tumors | P1P2 | Recruiting | 350 | Open-label | ORIC-114, Chemotherapy drug |
| NCT05413421 Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Metastatic Prostate Cancer | P1 | Recruiting | 275 | Open-label | ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets |
| NCT06816992 ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | Solid Tumors, EGFR Exon 20 Insertion Mutations | P1 | Recruiting | 76 | Open-label | ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab |
| NCT03324555 Study of ORIC-101 in Healthy Adult Subjects | Healthy Volunteers | P1 | Completed | 24 | Open-label | ORIC-101 |
| NCT03928314 Study of ORIC-101 in Combination With Anticancer Therapy | Solid Tumor | P1 | Terminated | 83 | Open-label | ORIC-101, Nab-paclitaxel |
| NCT06012721 Effect of Food on the Pharmacokinetics of ORIC-114 | Food Effect in Healthy Participants | P1 | Completed | 32 | RCT, Open-label | ORIC-114 |
| NCT04033328 Study of ORIC-101 in Combination With Enzalutamide | Prostatic Neoplasms | P1 | Terminated | 41 | Open-label | ORIC-101, enzalutamide 40 MG oral capsule [Xtandi] |
| NCT05227144 Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | P1 | Completed | 31 | Open-label | ORIC-533 |
| NCT03835637 Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects | Healthy Volunteers | P1 | Completed | 32 | Open-label | ORIC-101 |